Clinical Trial

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
Protocol Amendment History 4 changes
notable Trial sites expanded: 40 -> 44 locations 2026-07-11
notable Trial sites expanded: 34 -> 38 locations 2026-06-13
notable Trial sites expanded: 30 -> 34 locations 2026-05-16
notable Trial sites expanded: 23 -> 28 locations 2026-03-31
Trial Details
NCT Number NCT06401044
Lead Sponsor Amgen
Conditions Thyroid Eye Disease
Enrollment 88 participants
Start Date 2024-05-30
Primary Completion 2027-02-22 (estimated)
Study Completion 2027-08-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-10